You are here: REPAIR trial homepage
| PROTOCOL |
 |
This research is funded by the Efficacy and
Mechanism Evaluation (EME) programme. The EME programme is funded
by the MRC and managed by the NIHR Evaluation, Trials and Studies
Coordinating Centre (NETSCC), based at the University of Southampton |
|
Renal protection against ischaemia-reperfusion in transplantation: a randomised double blind placebo-controlled trial of 400 living-donor renal transplant patients ISRCTN30083294 |
|
|
406 patients randomised Recruitment has now closed Many thanks to everyone involved for helping to exceed our target |
|
The purpose of the trial is to determine if remote ischaemic preconditioning (RIPC) improves renal function after transplantation. Primary objective
|
|
| Secondary
objectives To determine the effects of RIPC on 1. Rate of fall in creatinine in the first 72 hours after transplantation 2. Inflammatory response to surgery in the first 5 days after transplantation 3. Protein expression in kidney parenchyma samples using histochemistry 4. Protein activation and expression in renal vasculature using immunoblotting 5. Kidney fibrosis 6 months after transplantation 6. Alloreactivity of T cells in the first 18 months after transplantation 7. Patient outcomes 2-5 years after transplantation using renal registry data |
|
| Inclusion
criteria 1. Patients undergoing living donor transplantation 2. Patients aged 18 years and above |
|
|
Exclusion criteria 1. Patients on ATP-sensitive potassium channel opening or blocking drugs 2. Patients on ciclosporin 3. Patients with a known iodine sensitivity (who cannot undergo iohexol clearance studies) 4. Patients with ABO incompatability 5. Any patient requiring HLA antibody removal therapy |